{"id":"solifenacin-for-24-weeks","safety":{"commonSideEffects":[{"rate":"11-27%","effect":"Dry mouth"},{"rate":"9-15%","effect":"Constipation"},{"rate":"2-5%","effect":"Blurred vision"},{"rate":"1-2%","effect":"Urinary retention"},{"rate":"2-4%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Solifenacin is a selective antagonist of the M3 muscarinic acetylcholine receptor, which is abundant in bladder detrusor muscle. By blocking these receptors, it inhibits acetylcholine-mediated smooth muscle contractions, thereby increasing bladder capacity and reducing the frequency and urgency of micturition. This mechanism makes it effective for treating overactive bladder symptoms.","oneSentence":"Solifenacin blocks muscarinic M3 receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:46.856Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urgency, frequency, and urge incontinence"}]},"trialDetails":[{"nctId":"NCT01767519","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-03-01","conditions":"Overactive Bladder, Urinary Incontinence","enrollment":356},{"nctId":"NCT01876186","phase":"PHASE4","title":"Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2013-05","conditions":"Overactive Bladder Syndrome","enrollment":200},{"nctId":"NCT02452879","phase":"NA","title":"Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2014-10","conditions":"Overactive Bladder","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vesicare"],"phase":"marketed","status":"active","brandName":"Solifenacin for 24 weeks","genericName":"Solifenacin for 24 weeks","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Solifenacin blocks muscarinic M3 receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. Used for Overactive bladder with symptoms of urgency, frequency, and urge incontinence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}